# A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

> **NCT02547935** · PHASE2,PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 459 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus, CKD and Albuminuria

## Interventions

- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Saxagliptin 2.5 mg
- **DRUG:** Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg

## Key facts

- **NCT ID:** NCT02547935
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-21
- **Primary completion:** 2018-05-18
- **Final completion:** 2018-05-18
- **Target enrollment:** 459 (ACTUAL)
- **Last updated:** 2019-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02547935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02547935, "A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02547935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*